OMONTYS
LOE ApproachingNDAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Mar 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMONTYS is an intravenous and subcutaneous solution approved in 2012 by Takeda. The specific indication and mechanism of action are not publicly detailed in available data. It represents a mature biologic therapeutic with defined IV/SC administration routes.
LOE Approaching1mo to LOE
Product faces imminent loss of exclusivity with minimal competitive pressure (25), signaling contraction of commercial team and transition from growth to defense strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on OMONTYS at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.